Exhibits several functions, including Hsp90 protein binding activity; chaperone binding activity; and enzyme binding activity. Involved in several processes, including intrinsic apoptotic signaling pathway in response to oxidative stress; nervous system development; and positive regulation of long-term synaptic depression. Localizes to several cellular components, including the cytoplasmic side of plasma membrane; cytosol; and neuron projection. Predicted to colocalize with the membrane. Used to study cerebrovascular disease (multiple); cognitive disorder (multiple); epilepsy; obesity; and tauopathy (multiple). Biomarker of middle cerebral artery infarction. Human ortholog(s) of this gene implicated in brain disease (multiple); dementia (multiple); and neurodegenerative disease (multiple). Orthologous to human MAPT (microtubule associated protein tau); PARTICIPATES IN Reelin signaling pathway; Alzheimer's disease pathway; mitogen activated protein kinase signaling pathway; INTERACTS WITH (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE; 1-[(4-chlorophenyl)-phenylmethyl]-4-methylpiperazine; 2,4-dibromophenyl 2,4,5-tribromophenyl ether.
[N-(4-methoxybenzyl)-N'-(5-nitro-1, 3-thiazol-2-yl)urea results in decreased activity of GSK3B protein] inhibits the reaction [Okadaic Acid results in increased phosphorylation of MAPT protein]
Lithium inhibits the reaction [Acrolein results in increased phosphorylation of MAPT protein], SB 203580 inhibits the reaction [Acrolein results in increased phosphorylation of MAPT protein]
[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of MAPT mRNA, Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of MAPT mRNA]
[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of MAPT mRNA, Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of MAPT mRNA]
[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of MAPT mRNA, Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of MAPT mRNA]
[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of MAPT mRNA, Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of MAPT mRNA]
[[Cadmium Chloride results in decreased activity of CHRM1 protein] which affects the expression of ACHE mRNA alternative form] which results in increased expression of MAPT protein more ...
[Dietary Fats co-treated with Cholesterol] results in increased expression of MAPT protein modified form, Selenium inhibits the reaction [[Dietary Fats co-treated with Cholesterol] results in increased expression of MAPT protein modified form]
cilostazol affects the acetylation of and affects the phosphorylation of MAPT protein, SIRT1 protein affects the reaction [cilostazol affects the acetylation of and affects the phosphorylation of MAPT protein]
Copper promotes the reaction [[PSEN1 gene mutant form co-treated with APP gene mutant form co-treated with MAPT gene mutant form] results in decreased expression of CPLX1 protein], Copper promotes the reaction [[PSEN1 gene mutant form co-treated with APP gene mutant form co-treated with MAPT gene mutant form] results in decreased expression of CPLX2 protein]
Copper promotes the reaction [[PSEN1 gene mutant form co-treated with APP gene mutant form co-treated with MAPT gene mutant form] results in decreased expression of CPLX1 protein], Copper promotes the reaction [[PSEN1 gene mutant form co-treated with APP gene mutant form co-treated with MAPT gene mutant form] results in decreased expression of CPLX2 protein]
Copper promotes the reaction [[PSEN1 gene mutant form co-treated with APP gene mutant form co-treated with MAPT gene mutant form] results in decreased expression of CPLX1 protein], Copper promotes the reaction [[PSEN1 gene mutant form co-treated with APP gene mutant form co-treated with MAPT gene mutant form] results in decreased expression of CPLX2 protein]
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAPT mRNA
Folic Acid inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form co-treated with MAPT protein mutant form] results in decreased expression of BAD protein modified form] more ...
Heparin promotes the reaction [MAPT protein binds to MAPT protein], Mercuric Chloride promotes the reaction [Heparin promotes the reaction [MAPT protein binds to MAPT protein]]
lead acetate affects the reaction [MAPT protein affects the abundance of CDK5R1 protein modified form], lead acetate results in increased expression of and results in increased phosphorylation of MAPT protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Lithium Chloride inhibits the reaction [Okadaic Acid affects the phosphorylation of MAPT protein]], Lithium Chloride inhibits the reaction [Okadaic Acid affects the phosphorylation of MAPT protein]
[Lithium Chloride results in decreased activity of GSK3B protein] inhibits the reaction [manganese chloride results in increased phosphorylation of MAPT protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Lithium Chloride inhibits the reaction [Okadaic Acid affects the phosphorylation of MAPT protein]]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [manganese chloride results in increased phosphorylation of MAPT protein] more ...
Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of MAPT mRNA], Melatonin inhibits the reaction [Wortmannin results in increased phosphorylation of MAPT protein]
[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of MAPT mRNA, Diethylnitrosamine results in increased expression of and results in increased phosphorylation of MAPT protein
[5-iodo-3-(2-azetidinylmethoxy)pyridine binds to and results in increased activity of CHRNB2 protein] inhibits the reaction [Okadaic Acid results in increased phosphorylation of MAPT protein] more ...
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Lithium Chloride inhibits the reaction [Okadaic Acid affects the phosphorylation of MAPT protein]] more ...
[oxophenylarsine results in increased activity of MARK1 protein] which results in increased phosphorylation of MAPT protein, Staurosporine inhibits the reaction [oxophenylarsine results in increased phosphorylation of MAPT protein]
[Zinc co-treated with pyrithione] results in increased phosphorylation of MAPT protein, GSK3B protein promotes the reaction [[Zinc co-treated with pyrithione] results in increased phosphorylation of MAPT protein]
resveratrol inhibits the reaction [APP protein modified form results in increased expression of MAPT protein modified form], resveratrol inhibits the reaction [APP protein modified form results in increased expression of MAPT protein]
SB 203580 inhibits the reaction [Acrolein results in increased phosphorylation of MAPT protein], SB 203580 inhibits the reaction [cyanoginosin LR results in increased phosphorylation of MAPT protein]
SB 203580 inhibits the reaction [cyanoginosin LR results in increased localization of MAPT protein], SB 203580 inhibits the reaction [cyanoginosin LR results in increased phosphorylation of MAPT protein]
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAPT mRNA
tauroursodeoxycholic acid inhibits the reaction [[APP protein modified form results in increased activity of CASP3 protein] which results in increased cleavage of MAPT protein]
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAPT mRNA
Melatonin inhibits the reaction [wortmannin results in increased phosphorylation of MAPT protein], Vitamin E inhibits the reaction [wortmannin results in increased phosphorylation of MAPT protein]
[Zinc co-treated with pyrithione] results in increased phosphorylation of MAPT protein, GSK3B protein promotes the reaction [[Zinc co-treated with pyrithione] results in increased phosphorylation of MAPT protein]
[Zinc co-treated with pyrithione] results in increased phosphorylation of MAPT protein, GSK3B protein promotes the reaction [[Zinc co-treated with pyrithione] results in increased phosphorylation of MAPT protein]
Target capture sequencing of exons and conserved non-coding sequences. Provided by: Dr. Mikita Suyama (Kyushu University) and Dr. Takashi Kuramoto (Kyoto University)
Publications:
Yoshihara M, etal., Genom Data. 2016 Nov 14;10:155-157. eCollection 2016 Dec.
Target capture sequencing of exons and conserved non-coding sequences. Provided by: Dr. Mikita Suyama (Kyushu University) and Dr. Takashi Kuramoto (Kyoto University)
Publications:
Yoshihara M, etal., Genom Data. 2016 Nov 14;10:155-157. eCollection 2016 Dec.
Target capture sequencing of exons and conserved non-coding sequences. Provided by: Dr. Mikita Suyama (Kyushu University) and Dr. Takashi Kuramoto (Kyoto University)
Publications:
Yoshihara M, etal., Genom Data. 2016 Nov 14;10:155-157. eCollection 2016 Dec.
Target capture sequencing of exons and conserved non-coding sequences. Provided by: Dr. Mikita Suyama (Kyushu University) and Dr. Takashi Kuramoto (Kyoto University)
Publications:
Yoshihara M, etal., Genom Data. 2016 Nov 14;10:155-157. eCollection 2016 Dec.
Target capture sequencing of exons and conserved non-coding sequences. Provided by: Dr. Mikita Suyama (Kyushu University) and Dr. Takashi Kuramoto (Kyoto University)
Publications:
Yoshihara M, etal., Genom Data. 2016 Nov 14;10:155-157. eCollection 2016 Dec.
Target capture sequencing of exons and conserved non-coding sequences. Provided by: Dr. Mikita Suyama (Kyushu University) and Dr. Takashi Kuramoto (Kyoto University)
Publications:
Yoshihara M, etal., Genom Data. 2016 Nov 14;10:155-157. eCollection 2016 Dec.
Target capture sequencing of exons and conserved non-coding sequences. Provided by: Dr. Mikita Suyama (Kyushu University) and Dr. Takashi Kuramoto (Kyoto University)
Publications:
Yoshihara M, etal., Genom Data. 2016 Nov 14;10:155-157. eCollection 2016 Dec.
Target capture sequencing of exons and conserved non-coding sequences. Provided by: Dr. Mikita Suyama (Kyushu University) and Dr. Takashi Kuramoto (Kyoto University)
Publications:
Yoshihara M, etal., Genom Data. 2016 Nov 14;10:155-157. eCollection 2016 Dec.
Target capture sequencing of exons and conserved non-coding sequences. Provided by: Dr. Mikita Suyama (Kyushu University) and Dr. Takashi Kuramoto (Kyoto University)
Publications:
Yoshihara M, etal., Genom Data. 2016 Nov 14;10:155-157. eCollection 2016 Dec.
Target capture sequencing of exons and conserved non-coding sequences. Provided by: Dr. Mikita Suyama (Kyushu University) and Dr. Takashi Kuramoto (Kyoto University)
Publications:
Yoshihara M, etal., Genom Data. 2016 Nov 14;10:155-157. eCollection 2016 Dec.
Target capture sequencing of exons and conserved non-coding sequences. Provided by: Dr. Mikita Suyama (Kyushu University) and Dr. Takashi Kuramoto (Kyoto University)
Publications:
Yoshihara M, etal., Genom Data. 2016 Nov 14;10:155-157. eCollection 2016 Dec.
Target capture sequencing of exons and conserved non-coding sequences. Provided by: Dr. Mikita Suyama (Kyushu University) and Dr. Takashi Kuramoto (Kyoto University)
Publications:
Yoshihara M, etal., Genom Data. 2016 Nov 14;10:155-157. eCollection 2016 Dec.
Target capture sequencing of exons and conserved non-coding sequences. Provided by: Dr. Mikita Suyama (Kyushu University) and Dr. Takashi Kuramoto (Kyoto University)
Publications:
Yoshihara M, etal., Genom Data. 2016 Nov 14;10:155-157. eCollection 2016 Dec.
Target capture sequencing of exons and conserved non-coding sequences. Provided by: Dr. Mikita Suyama (Kyushu University) and Dr. Takashi Kuramoto (Kyoto University)
Publications:
Yoshihara M, etal., Genom Data. 2016 Nov 14;10:155-157. eCollection 2016 Dec.
Target capture sequencing of exons and conserved non-coding sequences. Provided by: Dr. Mikita Suyama (Kyushu University) and Dr. Takashi Kuramoto (Kyoto University)
Publications:
Yoshihara M, etal., Genom Data. 2016 Nov 14;10:155-157. eCollection 2016 Dec.
Target capture sequencing of exons and conserved non-coding sequences. Provided by: Dr. Mikita Suyama (Kyushu University) and Dr. Takashi Kuramoto (Kyoto University)
Publications:
Yoshihara M, etal., Genom Data. 2016 Nov 14;10:155-157. eCollection 2016 Dec.
Target capture sequencing of exons and conserved non-coding sequences. Provided by: Dr. Mikita Suyama (Kyushu University) and Dr. Takashi Kuramoto (Kyoto University)
Publications:
Yoshihara M, etal., Genom Data. 2016 Nov 14;10:155-157. eCollection 2016 Dec.
Target capture sequencing of exons and conserved non-coding sequences. Provided by: Dr. Mikita Suyama (Kyushu University) and Dr. Takashi Kuramoto (Kyoto University)
Publications:
Yoshihara M, etal., Genom Data. 2016 Nov 14;10:155-157. eCollection 2016 Dec.
Target capture sequencing of exons and conserved non-coding sequences. Provided by: Dr. Mikita Suyama (Kyushu University) and Dr. Takashi Kuramoto (Kyoto University)
Publications:
Yoshihara M, etal., Genom Data. 2016 Nov 14;10:155-157. eCollection 2016 Dec.
Target capture sequencing of exons and conserved non-coding sequences. Provided by: Dr. Mikita Suyama (Kyushu University) and Dr. Takashi Kuramoto (Kyoto University)
Publications:
Yoshihara M, etal., Genom Data. 2016 Nov 14;10:155-157. eCollection 2016 Dec.
Gene-Chemical Interaction Annotations
